CTRI/2021/11/038338
Recruiting
未知
Prospective, Multinational, observational registry utilizing a cloud-based eCRF accessible to investigators. This registry will be open to all physicians managing T2DM, HF or CKD across the world
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- AstraZeneca Pharma India Ltd
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. ââ?°Â¥18 years old
- •2\. Having type 2 diabetes, CKD and/or HF
- •3\. Providing written informed consent to participate in the study
Exclusion Criteria
- •1\. Having any life\-threatening co\-morbidity and a life expectancy of less than 1 year
- •2\. Participating in any interventional trial requiring informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Multinational Observational Registry Collecting Data on safety and efficacy profile of Patients with Chronic Hepatitis D Virus Infection Receiving Treatment with BulevirtideB18.0Chronic viral hepatitis B with delta-agentDRKS00023867MYR GmbH45
Active, not recruiting
Not Applicable
A Multinational Observational Registry Collecting Data on the Clinical Profile and Treatment of Patients with Chronic Hepatitis D Virus InfectioB18.0Chronic viral hepatitis B with delta-agentDRKS00024538MYR GmbH1
Recruiting
Not Applicable
Metastatic ColoRectal cancer India RegistryHealth Condition 1: C189- Malignant neoplasm of colon, unspecifiedCTRI/2022/07/043968Dr Reddys Laboratories
Not yet recruiting
Not Applicable
Study of Management of Large Bone Defects.CTRI/2024/05/066962AO Innovation Translation Center (AO ITC)
Completed
Phase 1
A multicentre, multinational prospective observational imaging biomarker study in early stage Huntington?s disease (HD) patients to assess imaging techniques and parameters able to support efficacy studies with SEN0014196 in HD patients during Phase II and III studiesISRCTN26193242Siena Biotech (Italy)60